We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$393M
AUM Growth
+$191M
Cap. Flow
+$179M
Cap. Flow %
45.64%
Top 10 Hldgs %
69.35%
Holding
62
New
18
Increased
13
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
GEHC icon
GE HealthCare
GEHC
+$32.2M
2
LH icon
Labcorp
LH
+$32M
3
GSK icon
GSK
GSK
+$17.2M
4
GMED icon
Globus Medical
GMED
+$8.27M
5
PDCO
Patterson Companies, Inc.
PDCO
+$6.75M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$27.4M
2
COR icon
Cencora
COR
+$20.5M
3
MDT icon
Medtronic
MDT
+$6.77M
4
AVTR icon
Avantor
AVTR
+$5.99M
5
RLAY icon
Relay Therapeutics
RLAY
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 71.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.12B
$3.23M 0.82%
1,010,701
+62,244
+7% +$146K
ARQT icon
27
Arcutis Biotherapeutics
ARQT
$3.36B
$2.79M 0.71%
+293,047
New +$3.25M
VRAY
28
DELISTED
ViewRay, Inc.
VRAY
$2.27M 0.58%
+6,431,349
New +$6.66M
IDYA icon
29
IDEAYA Biosciences
IDYA
$3.42B
$1.75M 0.45%
74,594
+4,594
+7% +$94.5K
NYXH
30
Nyxoah
NYXH
$140M
$1.6M 0.41%
200,076
+11,201
+6% +$91.2K
INGN icon
31
Inogen
INGN
$175M
$1.29M 0.33%
111,535
-10,000
-8% -$118K
CRBP icon
32
Corbus Pharmaceuticals
CRBP
$166M
$1.18M 0.3%
150,000
– –
FUSN
33
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$1.15M 0.29%
246,036
– –
ASLN
34
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$928K 0.24%
31,769
– –
APRE icon
35
Aprea Therapeutics
APRE
$7.68M
$882K 0.22%
280,000
– –
RPTX
36
DELISTED
Repare Therapeutics
RPTX
$805K 0.2%
76,049
-152,489
-67% -$1.57M
VNDA icon
37
Vanda Pharmaceuticals
VNDA
$307M
$676K 0.17%
102,528
-21,269
-17% -$136K
MODD icon
38
Modular Medical
MODD
$12.9M
$675K 0.17%
22,978
– –
NXTC icon
39
NextCure
NXTC
$16.8M
$234K 0.06%
10,833
– –
MBRX icon
40
Moleculin Biotech
MBRX
$2.83M
$176K 0.04%
809
-1,887
-70% -$498K
VINC
41
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$133K 0.03%
5,102
– –
CMAX
42
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$95.6K 0.02%
1,025
– –
RCKTW icon
43
Rocket Pharmaceuticals Warrant
RCKTW
$149K
$78K 0.02%
400,000
– –
HUMAW icon
44
Humacyte Inc Warrant
HUMAW
$1.55M
$35.8K 0.01%
49,998
– –
KYNB
45
Kyntra Bio
KYNB
$27.2M
$31.3K 0.01%
+464
New +$192K
KYNB
46
PUT
Kyntra Bio
KYNB
$27.2M
$31.3K 0.01%
+464
New +$192K
CMAXW
47
DELISTED
CareMax, Inc. Warrant
CMAXW
$4.72K ﹤0.01%
12,808
– –
AVTR icon
48
Avantor
AVTR
$9.32B
– –
-283,136
Closed -$5.99M
CNC icon
49
Centene
CNC
$30.7B
– –
-432,834
Closed -$27.4M
COR icon
50
Cencora
COR
$60.6B
– –
-128,164
Closed -$20.5M
1
2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Sio Capital Management held 62 positions worth $393M, up 94% from $202M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sio Capital Management deployed $179M of net new capital in Q2 2023, opening 18 new positions and adding to 13 existing holdings. Its largest new stake was Labcorp: 165,179 shares worth $34.2M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Repare Therapeutics, an estimated $1.57M trimmed.

  • Sio Capital Management's largest Q2 2023 buy was Labcorp: 165,179 shares worth $34.2M.
  • Sio Capital Management added most to GE HealthCare in Q2 2023, an estimated $32.2M increase.
  • Sio Capital Management's biggest Q2 2023 reduction was Repare Therapeutics, cutting an estimated $1.57M.
  • Sio Capital Management fully exited Centene in Q2 2023, selling an estimated $27.4M.
  • Sio Capital Management's ten largest holdings make up 69% of its $393M portfolio in Q2 2023.
  • Sio Capital Management opened 18 new positions and closed 15 in Q2 2023.
  • Sio Capital Management's portfolio value rose 94% quarter-over-quarter to $393M.

Based on Sio Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.